Clin2
NCT06702826Likely a fitRecruiting

Cadonilimab plus radiation for lung cancer brain mets

Non Small Cell Lung CancerBrain MetastasesStereotactic RadiationImmunotherapy

Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.

This trial tests a combination of a targeted immunotherapy drug (cadonilimab) with a precise type of radiation to treat brain tumors that have grown after initial lung cancer treatment. The goal is to see if this approach can safely shrink brain metastases and improve outcomes.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
20 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You must be between 18 and 75 years old.
  • You must have non-small cell lung cancer and it has spread to your brain.
  • You must have already had one first treatment (like chemo or immunotherapy) and the cancer got worse.
  • Your brain tumors need to be small enough for a special, precise type of radiation (stereotactic radiosurgery).
  • You must not have serious health issues like autoimmune diseases, uncontrolled infections, or other cancers in the last 5 years.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05584267Recruiting· Phase 2
Immunotherapy plus targeted brain radiation for lung cancer

This Phase 2 trial studies whether giving immunotherapy along with a precise form of brain radiation can control brain metastases from non-small cell lung cancer. It may help by shrinking or stabilizing spots in the brain while your body’s immune system is also activated.

Changsha, Hunan
NCT07234877Not yet recruiting· Phase 2
Radiation plus immunotherapy vs immunotherapy alone for NSCLC brain mets

This trial tests if adding targeted radiation to a combination of immunotherapy (Ivonescimab) and chemotherapy works better than the drugs alone for people with non-small cell lung cancer (NSCLC) that has spread to the brain. It is for patients who have not had prior treatment for their advanced lung cancer.

Linz
NCT06467500Recruiting· Phase 2
Cadonilimab plus chemo for lung cancer after immunotherapy

This trial tests a new drug called cadonilimab combined with chemotherapy for people with advanced lung cancer who have already tried and failed immunotherapy. It aims to see if this combination can help when standard immunotherapy no longer works.

Yichang
NCT07535463Recruiting· Phase 1/Phase 2
Ivonescimab, chemotherapy, and radiation for lung cancer with brain tumors

This study tests a combination of a new immunotherapy drug (ivonescimab), standard chemotherapy, and focused radiation (stereotactic radiosurgery) for non-small cell lung cancer that has spread to the brain. The goal is to see if this combination can shrink tumors in both the lungs and brain.

Basking Ridge, New Jersey
NCT06501391Recruiting· Phase 2
Brain radiation plus chemo-immunotherapy for untreated NSCLC with stable brain metastases

This trial tests whether combining brain radiation with chemotherapy and immunotherapy can help people with advanced lung cancer that has spread to the brain but has not yet been treated. It is for those whose tumors do not have certain gene mutations (EGFR, ALK, ROS1).

Shanghai
NCT06582940Recruiting· Phase 2
MRI-guided radiation for lung cancer with brain metastases

This trial tests a new way to deliver radiation to brain metastases from non-small cell lung cancer, using MRI scans to guide the treatment and reduce the area exposed. The goal is to see if this approach is safe and effective while possibly lowering side effects.

Guangzhou, Guangdong

Hear when a new Non Small Cell Lung Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.